Efficacy and Safety of 0.25% Desoximetasone Cream (Topoxy®) in the Treatment of Scalp Psoriasis

Launched by SIRIRAJ HOSPITAL · Apr 20, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years
• • 2. Diagnosed with scalp psoriasis by dermatologist
• • 3. Has scalp psoriasis Involve ≥ 10% of total scalp area and also has clinical signs, or a previous diagnosis, of psoriasis on the trunk and/or limbs
• • 4. Total severity of scalp psoriasis should be graded in mild to very severe according to Investigator's Global Assessment score (IGA)
• • 5. Clinical signs (redness, thickness, scaliness) should be scored as "Moderate" for at least 1 sign and "slight" on each of the other two signs
• • 6. All participants agree to participate in the study and already complete and sign consent form
• Exclusion Criteria:
• • 1. Treated with these medications before including in the study
• • Topical corticosteroid for scalp psoriasis (except emollients and shampoo) within 2 weeks
• • Very potent topical corticosteroids for psoriasis on other area or Narrow band Ultraviolet B (NB-UVB) within 2 weeks
• • Oral psoralen plus Ultraviolet A (PUVA) or oral medication (Methotrexate, Acitretin, Cyclosporine) within 4 weeks
• • Biologic agents or concomitant medication that could affect scalp psoriasis (Beta- blockers, Antimalarial drugs, Lithium ) within 6 months
• • 2. Has skin infection or atrophic skin on the scalp
• • 3. Has history of allergic reaction or hypersensitivity to 0.25% Desoximetasone
• • 4. Female participants with pregnancy or in lactation period
• • 5. Participants who unable to come for follow-up visits at hospital
• • 6. Participants with other underlying disease e.g. diabetes mellitus, hypertension, thyroid disease
• • 7. Vulnerable subject e.g. illiterate person